Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2246]

Problems in the structure of clinical trials

Prof Thomas Tursz – Institut Gustave Roussy, Paris, France

Problems in the structure of clinical trials ( Prof Thomas Tursz – Institut Gustave Roussy, Paris, France )

New approaches to personalised medicine

Prof Jens Ricke – Otto-Von-Guericke-University, Magdeburg, Germany

New approaches to personalised medicine ( Prof Jens Ricke – Otto-Von-Guericke-University, Magdeburg, Germany )

Heterogeneity of tumours and the challenges of biomarker development

Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy

Heterogeneity of tumours and the challenges of biomarker development ( Prof Giuseppe Curigliano – European Institute of Oncology, Milan, Italy )

Cancer genes differ in different parts of a tumour

Prof Charles Swanton - CRUK London Research Institute and UCL, UK

Cancer genes differ in different parts of a tumour ( Prof Charles Swanton - CRUK London Research Institute and UCL, UK )

Targeting DNA damage response and repair excluding PARP for triple negative...

Prof Thomas Helleday - Karolinska Institutet, Stockholm, Sweden

Targeting DNA damage response and repair excluding PARP for triple negative breast cancer ( Prof Thomas Helleday - Karolinska Institutet, Stockholm, Sweden )

Endocrine therapy resistance and next generation sequencing

Prof Matthew Ellis - Washington University, USA

Endocrine therapy resistance and next generation sequencing ( Prof Matthew Ellis - Washington University, USA )

Molecular characterisation of breast cancer: the mutational landscape

Prof Sam Aparicio - University of British Columbia, Vancouver, Canada

Molecular characterisation of breast cancer: the mutational landscape ( Prof Sam Aparicio - University of British Columbia, Vancouver, Canada )

New cyclin-dependent kinase inhibitor with letrozole for ER+/HER2- breast cancer

Prof Richard Finn - Universtity of California, Los Angeles, USA

New cyclin-dependent kinase inhibitor with letrozole for ER+/HER2- breast cancer ( Prof Richard Finn - Universtity of California, Los Angeles, USA )

Metabolism in malignant tumors: a new approach for treating breast cancer

Prof Tak Mak - University of Toronto, Canada

Metabolism in malignant tumors: a new approach for treating breast cancer ( Prof Tak Mak - University of Toronto, Canada )

Criteria required before implementation of whole genome arrays in clinical...

Prof Daniel Hays - University of Michigan, Ann Arbor, USA

Criteria required before implementation of whole genome arrays in clinical practice ( Prof Daniel Hays - University of Michigan, Ann Arbor, USA )

Evidence for TORC1 activation marker as a predictive factor for everolimus...

Dr Thomas Bachelot - Centre Leon Berard, Lyon, France

Evidence for TORC1 activation marker as a predictive factor for everolimus efficacy in metastatic breast cancer ( Dr Thomas Bachelot - Centre Leon Berard, Lyon, France )

Implementing symptom guidelines

Anita Margulies - EONS and the Swiss Oncology Nursing Society

Implementing symptom guidelines ( Anita Margulies - EONS and the Swiss Oncology Nursing Society )

More from ecancer